Abstract:BACKGROUND: Mutations in POLE /POLD1 proofreading domain can cause deficiencies in DNA repair, conferring ultramutated cancer phenotypes. Preliminary clinical studies have revealed an association between POLE/POLD1 mutations and beneficial clinical outcomes to immune checkpoint inhibitor (ICI) therapy This study aims to investigate the genomic characteristics of POLE/POLD-mutant tumors and the prognostic value of POLE/POLD mutation for ICI treatment.METHODS: Genomic data of 21,074 patients with 23 cancer types were retrieved from Burning Rock variant database (BR VarDB). The prevalence and spectra of POLE and POLD1 mutations were assessed and compared with that in The Cancer Genome Atlas (TCGA) samples. The correlations of POLE/POLD1 mutation with tumor mutational burden (TMB) and microsatellite instability (MSI) were investigated. The prognostic value of POLE/POLD1 mutations was also explored in 2,487 ICI-treated patients from published studies.RESULTS: BR VarDB samples displayed a similar mutational prevalence of POLE (3.2% vs. 3.2%) and POLD1 (1.4% vs. 1.6%, P=0.248) versusTCGA samples, but a slightly lower frequency of POLE and POLD1 co-mutations (0.21% vs. 0.43%, P<0.001). POLE/POLD1-mutant tumors harbored increased TCT→TAT and TCG→TTG transversions, and genomic signatures associated with DNA mismatch repair (MMR) deficiency and ultra-hypermuation. Furthermore, tumors with POLE/POLD1 proofreading mutation showed a significantly higher TMB than tumors with non-proofreading mutations (P<0.01), although both possessed a higher TMB than POLE/POLD1 wild-type (WT) tumors (P<0.0001 and P<0.0001, respectively). MSI was commonly observed in tumors harboring dominant clone of POLE/POLD1 mutation (10.2%), but occurred rarely in POLE/POLD1 WT tumors (0.5%) and tumors with accumulating sub-cloned POLE/POLD1 mutation (0%). Survival analysis revealed that POLE/POLD1 mutation was not independently correlated with longer survival after adjusting for TMB and other factors (HR =0.86, P=0.372). However, patients harboring POLE/POLD1 mutation demonstrated a higher response rate than patients with POLE/ POLD1 WT tumors (35.2% vs. 19.6%, P=0.0165).CONCLUSIONS: We delineated distinctive genomic characteristics in POLE/POLD1-mutant tumors, suggesting the potential predictive role of POLE/POLD1 mutations, especially those in the proofreading domain, for beneficial outcomes of immunotherapy. Our results also suggest that MSI caused by a loss-of-function mutation in the MMR pathway tends to result from POLE/POLD1 proofreading deficiency in POLE/POLD1-mutant tumors with MSI.

Elevated DNA Polymerase Delta 1 Expression Correlates with Tumor Progression and Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma.

POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma

Characterization of Genomic Alterations, Tumor Mutational Burden and PDL1 Expression in 181 Chinese Hepatocellular Carcinomas.

Increased DNA Polymerase Epsilon Catalytic Subunit Expression Predicts Tumor Progression and Modulates Tumor Microenvironment of Hepatocellular Carcinoma

Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma

Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma

Pan-Cancer Analysis Reveals the Potential of PLOD1 As a Prognostic and Immune Biomarker for Human Cancer

Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma

Identification of CCDC115 As an Adverse Prognostic Biomarker in Liver Cancer Based on Bioinformatics and Experimental Analyses

An Alternative POLDIP3 Transcript Promotes Hepatocellular Carcinoma Progression.

Bioinformatics Analysis Combined with Experiments Predicts PUDP As a Potential Prognostic Biomarker for Hepatocellular Carcinoma Through Its Interaction with Tumor Microenvironment.

Clinical Significance of PD-1/PD-Ls Gene Amplification and Overexpression in Patients with Hepatocellular Carcinoma.

Systematic characterization of the expression, prognosis and immune characteristics of PLOD family genes in breast cancer

Expression Patterns of Programmed Death Ligand 1 Correlate with Different Microenvironments and Patient Prognosis in Hepatocellular Carcinoma.

Comprehensive analysis of POLH-AS1 as a prognostic biomarker in hepatocellular carcinoma

POH1 Contributes to Hyperactivation of TGF-β Signaling and Facilitates Hepatocellular Carcinoma Metastasis Through Deubiquitinating TGF-β Receptors and Caveolin-1

Biological characterization and clinical value of PLOD gene family in clear cell renal cell carcinoma

Integrated Profiling Identifies PLOD3 as a Potential Prognostic and Immunotherapy Relevant Biomarker in Colorectal Cancer

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor

Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma

DNA Polymerase Delta 1 Catalytic Subunit (POLD1) as a Prognostic Factor in Clear Cell Renal Cell Carcinoma Patients